Zentalis Pharmaceuticals, Inc. Research And Development Expense

Quick Answer

Zentalis Pharmaceuticals, Inc. reported Research And Development Expense of $107.30 million for the year ending 2025.

  • Zentalis Pharmaceuticals, Inc. showed a decrease of -36.0% in Research And Development Expense from 2024 to 2025.
  • This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Research And Development Expense has grown by 179.5%.
  • Historical annual values: Fiscal year 2025: $107.30 million | Fiscal year 2024: $167.77 million | Fiscal year 2023: $189.59 million | Fiscal year 2022: $172.73 million | Fiscal year 2021: $175.60 million | Fiscal year 2020: $84.90 million | Fiscal year 2019: $38.39 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: